Patent ID: 7618623

Claim:
A method for stably introducing a transgene into a cell in vivo with a single viral vector, comprising: contacting the cell with an adenovirus, wherein the adenovirus comprises adenoviral capsid proteins; and an adenoviral vector comprising (a) a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, wherein the 5′ and the 3′ retroviral LTR nucleic acid sequences are Moloney Leukemia Virus LTR nucleic acid sequences, (b) a retroviral nucleic acid sequence comprising a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, wherein the retroviral nucleic acid sequence does not comprise a nucleic acid sequence encoding a functional retroviral gag or a functional retroviral pol, or both, (c) a nucleic acid sequence encoding a transgene located between the 5, LTR and the 3′ LTR, wherein the adenoviral vector is replication-defective and has a functional deletion of a nucleic acid sequence encoding an early transcriptional unit polypeptide, thereby introducing the adenoviral vector into the cell, wherein the cell is not able to produce viral particles, and wherein no other viral vector is introduced into the cell, thereby stably introducing a transgene into a cell in vivo.